Expresión diferencial en placenta de beta-defensinas humanas y detección de variantes alélicas en el gen DEFB1 de madres positivas para VIH-1 by Aguilar-Jiménez, Wbeimar et al.
Biomédica 2011;31:44-54
44
Aguilar-Jiménez W, Zapata W, Rugeles MT
ARTÍCULO ORIGINAL
Differential expression of human beta defensins in placenta 
and detection of allelic variants in the DEFB1 gene from 
HIV-1 positive mothers
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Introduction. Low infection rates in neonates born to HIV-1-seropositive mothers highlight the existence 
of natural defense mechanisms in the maternal-fetal interface. Human beta defensins (HBDs) inhibit 
HIV-1 replication in vitro and their variants are associated with HIV-1 resistance/susceptibility.
Objective. Levels of HBD mRNA expression in placentas were obtained from seropositive and healthy 
mothers to determine whether HIV-1 infection induces anti-viral factors.
Materials and methods. HBD-1, -2 and -3 transcripts were quantified by real time RT-PCR, and A692G/
G1654A/A1836G variants in the DEFB1 gene were evaluated by sequencing.
Results. Transcript levels of HBD-1 were significantly higher, and those of HBD-3 were lower in placenta 
from seropositive mothers compared to controls. Additionally, simultaneous presence of the A692G A/G 
and A1836G G/G genotypes was associated with high expression of HBD-1 in all populations and the 
A692G variant in babies born to seropositive mothers was in Hardy-Weinberg disequilibrium.
Conclusion. Contrasting results in levels of HBDs were probably due to viral stimuli and suggest that 
HIV-1 induce a differential expression of HBDs in placenta and these proteins could be involved in 
protecting against HIV-1 at least early in pregnancy. However, it was not possible to associate  these 
findings directly with protection against HIV-1 vertical transmission since none of the newborn infants 
became infected.
Key words: human beta-defensins, placenta, HIV-1; immunity, innate; infectious disease transmission, 
vertical.
Expresión diferencial en placenta de beta-defensinas humanas y detección de variantes alélicas 
en el gen DEFB1 de madres positivas para VIH-1 
Introducción. Las bajas tasas de infección en neonatos nacidos de madres seropositivas para el 
VIH-1 resaltan la existencia de mecanismos de defensa natural en la interfase materno-fetal. Las beta-
defensinas humanas inhiben la replicación del VIH-1 in vitro y sus polimorfismos están asociados con 
la resistencia o susceptibilidad al VIH-1.
Objetivo. Comparar los niveles de expresión de ARNm de beta-defensinas humanas en placentas 
de madres seropositivas y en seronegativas para determinar si la infección por VIH-1 induce factores 
antivirales que pudieran proteger a los bebés de la transmisión del VIH-1.
Materiales y métodos. Los transcritos de HBD-1, 2 y 3 se cuantificaron por PCR en tiempo real y las 
variantes A692G/G1654A/A1836G del gen DEFB1 se evaluaron por secuenciación.
Resultados. Los niveles de transcritos de HBD-1 fueron significativamente mayores, y los de HBD-3 
fueron menores en placentas de madres seropositivas en comparación con los controles. Además, 
la presencia simultánea de los genotipos A692G A/G y A1836G G/G se asoció con alta expresión de 
HBD-1 en toda la población estudiada y la variante A692G estuvo en desequilibrio de Hardy-Weinberg 
en los bebés nacidos de madres seropositivas.
Conclusión. Los resultados contrastantes de los niveles de HBD se deben, probablemente, a estímulos 
virales y sugieren que el VIH-1 induce una expresión diferencial de beta-defensinas humanas en 
placenta y que estas proteínas podrían estar involucradas en la protección contra el VIH-1, al menos, 
en las etapas tempranas del embarazo. Sin embargo, no fue posible asociar estos hallazgos con 
la protección contra la transmisión vertical del VIH-1, puesto que ninguno de los bebés adquirió la 
infección.
Palabras clave: beta-defensinas; placenta; VIH-1, inmunidad innata, transmisión vertical de 
enfermedad infecciosa.
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Human beta defensins in placenta and vertical transmission of HIV-1
Similar to other infectious microorganisms, the 
type 1 human immunodeficiency virus (HIV-1) can 
be vertically transmitted to the fetus (1,2); in fact, 
most children acquire this infection through their 
mothers, in uterus, at delivery or during breast 
feeding (3-6). The rate of vertical transmission 
decreased markedly, from 15%-35% to 0.8%-3%, 
when pregnant women are given zidovudine (AZT) 
during pregnancy and their children are delivered 
by cesarean section (7-9).
The transplacental route of infection was the first 
identified mechanism of mother-to-fetus HIV-1 
transmission, after detection of HIV in fetal tissue in 
1985 (10,11). In fact, the fetus acquired the HIV-1 as 
early as eight weeks of gestation (12). Trophoblastic 
cells express CD4, CCR1, CCR3, CXCR4 and 
CCR5, all molecules involved in HIV-1 entry (13). 
In addition, reports have indicated that placental 
fibroblasts can act as viral reservoirs, capable of 
infecting other fetal cells (14). This relationship 
suggested avenues by which the fetus can acquire 
the infection by an alteration of the maternal-fetal 
barrier, by cell-to-cell contact from infected cells to 
trophoblastic cells or by HIV-1 transcytosis (15).
Cases have been documented of neonates born 
to seropositive (SP) mothers. These are known as 
HIV-1-exposed seronegatives (ESN), in whom a low 
rate of infection has been observed even in absence 
of preventive measures (16,17), a condition that 
indicates the existence of natural mechanisms for 
preventing infection during gestation.
The ∆32 mutation is the main genetic mechanism 
known to confer a high degree of resistance to 
HIV-1 infection (18,19). Homozygous individuals for 
the null allele are highly resistant to HIV-1 infection, 
and the heterozygous individuals exhibit a delay in 
AIDS progression, including children (18,20-22). 
However, the homozygous genotype is uncommon 
and explains only 3.6% of the resistant population 
to HIV-1 (23-25). In addition, the ∆32 mutation has 
not been found to confer protection against HIV-1 
vertical transmission (22,26,27). 
Several reports have indicated that soluble factors, 
secreted by various types of cells during the immune
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response, have strong antiviral activity as a primary 
function or as a “collateral” effect. At least 5 factors 
have been identified in the maternal-fetus interface: 
stromal α-chemokine derived factor-1 (SDF-1) (28), 
leukemia inhibitory factor (LIF) (29), alloantigen-
stimulated factor (ASF) (30), RNases associated 
with human chorionic gonadotropin (hCG) (31-33) 
and, most recently, the β and α-defensins (34-
36). Defensins are small cysteine-rich cationic 
peptides that exhibit antimicrobial activity against 
a broad spectrum of microorganisms (37). To date, 
six human β-defensin (HBD) have been identified 
and characterized (38). HBD-1 is constitutively 
expressed by epithelial cells, while HBD-2 and 3 
are induced by proinflammatory cytokines and 
microbes including viruses (39). Exposure of oral 
epithelial cells to HIV-1 induces mRNA expression 
for HBD-2 and -3. These defensins inhibit R5 
and X4 HIV-1 infection and replication by a direct 
interaction with virions and by down-regulation 
of the CXCR4 coreceptor expression (40,41). In 
addition, HBD-2 and -3 mRNA are increased in oral 
mucosa from ESN compared to healthy controls 
(HC) (42).
Thirty single-nucleotide polymorphisms (SNP) asso-
ciated with different ethnic groups have been 
reported in HBD genes, particularly in DEFB1 and 
DEFB2 that code for HBD-1 and 2 respectively 
(43). Previous SNP studies have suggested that 
-44 C/G (site 668), -20 A/G (site 692) and -52 
G/A (site 660) SNPs in DEFB1 are associated 
with differential risks of vertical transmission of 
HIV-1 (44-47). Furthermore, the frequency of the 
SNP genotype A692G G/G in the DEFB1 gene 
was significantly higher in ESN compared to 
SP individuals and suggested an association of 
this SNP with resistance to HIV-1 infection (42). 
Additional SNPs (692G, G1654A and A1836G) in 
the DEFB1 gene have characteristics that plausibly 
link them to differential gene expression or gene 
product function (43).
Expression of HBD-1, 2, and 3 mRNA in fetal 
membranes and placenta has been described 
previously (34,36). However, HBD expression levels 
in the placenta and other reproductive tissues have 
not been characterized as potential modifiers of the 
risk of HIV infection, nor has the influence of HIV-1 
in the induction of these factors been explored.
To determine if the transcriptional expression of 
these proteins is modulated by the exposure to 
HIV-1,  HBD-1, 2 and 3 mRNA levels in the placenta 
were quantified from HIV-1 positive and negative 
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Table 1. Demographic profile.
Characteristics HIV-1 negative mothers HIV-1 positive mothers 
 (n=38) (n=36)
Age* 
 Range in years (Median) 16-42 (23) 16-42 (25)
Gestational age at childbirth** 
 Range in weeks (Median) 36- 42 (39) 33-38 (37,5)
Number of pregnancies 
 Range (Median) 1-4 (2) 1-6 (2) 
Type of delivery*** Vaginal (n=38) Vaginal (n=1) 
  Cesarean (n=0) Cesarean (n=35)  
CD4+ T cell count 
 Range (Median) -- 48-990 (502) cell/mm3
Viral load 
 Range (Median) -- 202-147,000 (919) copies/mL
Antiretroviral treatment during pregnancy -- 35
Antiretroviral treatment 1 hour before and during delivery -- 35
*p=0.409     **p=0.0006 ***p<0.0001
mothers. In addition, the presence of A692G, 
G1654A and A1836G SNPs were determined in 
the DEFB1 gene.
An increased expression of HBD-1 mRNA and a 
decreased expression of HBD-3 mRNA was found in 
placentas from HIV-1 positive mothers. In addition, 
when the SNP genotypes A692G A/G and A1836G 
G/G were present simultaneously, they were 
associated with high expression of HBD-1 but not 
HBD-3. A final observation was that the frequency of 
A692G SNP was in Hardy Weinberg disequilibrium 
in children born to HIV-1 positive mothers.
Materials and methods
Study subjects and samples
The study enrolled 74 mothers and their infants 
between 2004 and 2005 from three hospitals in 
Medellín, Colombia: Hospital Universitario San 
Vicente de Paul, Hospital General and Clínica 
Prado. Thirty six HIV-1 positive pregnant women 
were included. Healthy controls (HC) were 38 
pregnant women volunteers with similar ethnic 
background to the seropositive (SP) individuals. 
The HC HIV-1 seronegative status was evaluated 
by an ELISA test, and presence of proviral DNA was 
ruled out in all HC samples by a negative nested 
PCR for env HIV-1 gene. Thirty five HIV-1-positive 
women received antiretroviral chemoprophylaxis 
during pregnancy, mainly zidovudine, (600 mg/
day) plus lamivudine (300 mg/day) (Combivir) 
and indinavir (800 mg/ every eight hours (q.8.h) 
or nelfinavir (750 mg q.8.h) or nevirapine (400 mg/
day) according to physician criteria. These women 
also received zidovudine 2 mg per kilogram weight 
during first hour (mg/kg/h) before cesarean section 
and 1 mg/kg/h during labor (Table 1). 
At the time of delivery, by labour or caesarean, a 
20 ml sample of peripheral blood was collected 
from the mother. 35-40 ml of cord blood and 
placenta tissue were stored in RNA later, (QIAgen, 
Valencia, CA) at -70°C. Approximately 2-3 ml sample 
of peripheral blood was obtained from neonates 
during the first 24 hrs postpartum and at 3 and 6 
months of age. By determination of viral load in 
these samples, the occurrence of perinatal infection 
was evaluated in newborns from HIV-1 positive 
women. At 18 months, an additional sample was 
taken to determine the presence of anti-HIV-1 
antibodies by an ELISA test. A clear explanation of 
the objectives and the implications of the results 
were given to each participant. An institutional-
approved informed consent was signed, according 
to Colombian government resolution 008430 of 
1993 legislation.
PCR amplification of CCR5 open reading frame 
(ORF)
The exon 4 of the CCR5 gene was amplified by PCR 
as previously described (23). The reactions were 
undertaken in a PTC-100 peltier Thermal Cycler 
(MJ research) with the following protocol: 95°C 3 
min, 30 cycles of amplification at 95°C x 30 s, 56°C 
x 30 s and 72°C x 30 s, and finally 72°C x 5 min. 
The PCR product was separated by electrophoresis 
in a 2% agarose gel, stained with “SYBR green” 
and visualized by UV transillumination. For the 
standard genotype (CCR5/CCR5), a 225bp PCR 
product was obtained, whereas a product of 193 
bp indicated a mutant homozygous genotype 
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(∆32/∆32). Presence of both bands indicated a 
heterozygous genotype (CCR5/∆32).
Restriction fragment length-polymorphisms 
(RFLPs) for SNPs A692G, G1654A and A1836G 
in the DEFB1 gene
Polymorphisms were determined by RFLP-PCR. 
The primer sequences and protocols were previously 
described (43). PCR products were digested in a 
final volume of 15 µL containing 1X buffer, 0.2 µL of 
the corresponding restriction enzyme and 4 µL of 
PCR product. The mixture was incubated for 16 h 
at 37°C. The enzymes used were Bme1390I for the 
A692G SNP, Bst11071 for the A1836G SNP, and 
HpyCH4V for the G1654A SNP. The SNPs were 
verified by sequencing using a commercial service 
from Macrogen (Macrogen, Seoul, Korea). The 
sequences were analyzed with MEGA software 
version 3.1. DEFB1 exon 1 and 2 DNA sequences 
provided by Genebank NCBI (accession numbers 
U50930 and U50931, respectively) were used as 
reference.
Real time RT-PCR assay to quantify HBD 
mRNA
Total RNA was extracted from epithelial cells with 
TRizolReagent (INVITROGEN), following the 
manufacturer’s instructions. The amount and purity 
of the RNA were determined by spectrometry at 
260/280 nm using the NanoDrop-1000 (Thermo 
Scientific). Isolated total RNA was treated with 
DNase I (Fermentas) to eliminate genomic DNA. 
cDNA was synthesized using the SuperScript 
III (Invitrogen) according to the manufacturer’s 
instructions. Each 25 µl-real-time PCR mixture 
consisted of 3 µl of cDNA, 1x reaction buffer, 5mM 
MgCl2, 0.2 mM dNTPs, 0.05U of platinum Taq DNA 
polymerase (Invitrogen), 0.2 µM of each primer and 
SYBR green dye diluted 1:2500 (Sigma, St. Louis. 
USA). The β-actin RNA was used to normalize 
the RNA content in each preparation. Thermal 
conditions and the oligonucleotides have been 
described previously (40,48,49).
The cycling profiles were: 95°C for 10 min followed 
by 45 cycles of 95°C for 15 s, 55°C for 30 s for 
HBD-1 (60°C for 30 s for HBD-2 and HBD-3, and 
55°C for 30 s for β-Actin) and 72°C for 30 s. We 
included a melting curve to confirm the specificity 
of the PCR product. The PCR products were 
separated by electrophoresis in a 2% agarose gel, 
stained with “SYBR green” and visualized by UV 
transillumination. The band size was estimated 
with HyperLadder II (Bioline). All real-time RT–
PCR amplifications were performed  in duplicate 
and data acquisition was via the Chromo 4TM 
detector, software 2.03 (MJ Research). Quantity of 
HBD mRNA was determined by ∆Ct method (50) 
normalized with the β-actin expression level. 
Statistical analysis 
Fisher’s-exact tests or chi-square tests were used 
to compare categorical variables. Differences in 
HBD mRNA expression levels were tested by 
Mann-Whitney statistic. Correlations between HBD 
mRNA expression level and immunological state 
of HIV-1 positive mothers were evaluated using 
Spearman’s rank correlation coefficient. A p<0.05 
was considered statistically significant. Analyses 
were performed using GraphPad Prism version 
5.0 (GraphPad Software, CA, USA). Allele and 
genotype frequencies, as well as Hardy-Weinberg 
equilibrium (HWE) were calculated with GENEPOP 
software version 3.4. (51). Additionally, ARLEQUIN 
version 3.1 (52) was used to test for differences in 
haplotype frequencies.
Results
Demographic data
Thirty-eight HIV-1 negative mothers, 36 HIV-1 
positive mothers and their infants were evaluated. 
One SP woman did not receive treatment during 
pregnancy or at delivery. Statistically significant 
differences were observed in gestational age; 33-
38 weeks (median= 37.5) for HIV-1 positive mothers 
and 36-42 weeks (median= 39) for HIV-1 negative 
mothers, (p<0.001). None of the neonates born to 
HIV-1 SP mothers acquired HIV-1 infection perinatally. 
Demographic data are described in table 1.
Low frequency of CCR5 ∆32 mutation in the 
entire population
Since the presence of the ∆32 mutation can skew 
the results, this mutation was evaluated in all 
subjects. None exhibited the homozygous ∆32 
genotype. Two infants born to SP mothers, two born 
to HC mothers and two SP mothers were delta-32/
CCR5 heterozygous. No difference was observed 
between the evaluated groups. In addition, ∆32 
was in Hardy-Weinberg equilibrium in the SP and 
HC groups, according to the expected frequencies 
(data not shown).
Hardy-Weinberg disequilibrium of A692G SNP 
in DEFB1 gene in babies born to SP mothers
When the allele and genotype frequencies were 
analyzed for the A692G, G1654A and A1836G SNPs 
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in SP and HC mothers and their infants, statistically 
significant differences were not observed (table 2). 
Similarly, the analysis of the observed vs expected 
frequencies under Hardy-Weinberg equilibrium 
model did not show statistically significant 
differences with one exception. The A692G SNP 
in the infants born to HIV-1 positive mothers was 
significantly deviant (p=0.0001) (table 3).
Increased expression of HBD-1 mRNA and 
decreased expression of HBD-3 mRNA in 
placenta from SP mothers
To determine if differences occurred in the 
expression of HBD-1, 2 or 3 mRNA among the 
studied groups, the number of mRNA copies was 
calculated in duplicate by RT-PCR from placenta 
tissue. The HBD-2 mRNA expression was examined 
in 20 placenta samples; it was detected in 2 
Table 2. Genotype and allele frequencies of DEFB1 SNPs.
 Genotypic frequencies Allelic frequencies
 n (Frequency) n (Frequency)
SNP Groups A/A A/G G/G A G
A692G HC Mothers 9 (0.29) 16 (0.52) 6 (0.19) 34 (0.55) 28 (0.45)
 Infants born to HC mothers 6 (0.20) 20 (0.67) 4 (0.13) 32 (0.53) 28 (0.47)
 SP Mothers 5 (0.18) 15 (0.56) 7 (0.26) 25 (0.46) 29 (0.54)
 Infants born to SP mothers 3 (0.11) 20 (0.71) 5 (0.18) 26 (0.46) 30 (0.54)
A1836G HC Mothers 22 (0.71) 9 (0.29) 0 (0) 53 (0.85) 9 (0.15) 
 Infants born to HC mothers 23 (0.77) 7 (0.23) 0 (0) 53 (0.88) 7 (0.12) 
 SP Mothers 27 (0.90) 3 (0.10) 0 (0) 57 (0.95) 3 (0.05)
 Infants born to SP mothers 24 (0.86) 4 (0.14) 0 (0) 53 (0.91) 5 (0.09)
G1654A HC Mothers 0 (0) 0 (0) 31 (1.00) 0 (0) 62 (1.00)
 Infants born to HC mothers 0 (0) 0 (0) 30 (1.00) 0 (0) 60 (1.00) 
 SP Mothers 0 (0) 0 (0) 30 (1.00) 0 (0) 60 (1.00)
 Infants born to SP mothers 0 (0) 0 (0) 29 (1.00) 0 (0) 58 (1.00) 
Table 3. Observed versus expected genotypic frequencies of DEFB1 SNPs. 
 Groups
 HC Mothers Babies born to  SP Mothers Babies born to
  HC mothers  SP mothers*
 
SNP Genotype  Obs Exp Obs Exp Obs Exp Obs Exp
 
A692G* A/A 9 9.2 6 8.40 5 5.6 3 5.9
 A/G 16 15.6 20 15.18 15 13.67 20 14.18 
 G/G 6 6.2 4 6.4 7 7.66 5 7.9
A1836G A/A 22 22.6 23 23.35 27 27.05 24 24.1
 A/G 9 7.8 7 6.28 3 2.89 4 3.8
 G/G 0 0.59 0 0.35 0 0.05 0 0.11 
G1654A A/A 31 31 30 30 30 30 30 30
 A/G 0 0 0 0 0 0 0 0
 G/G 0 0 0 0 0 0 0 0
* p=0.0001
samples from HC mothers and in 2 samples from 
SP mothers.
The presence of both defensins, HBD-1 and 
HBD-3, was observed in a significantly higher 
number of samples from SP mothers (15/36; 
41.7%) compared to samples from HC mothers 
(4/38; 10.5%); (p=0.003; figure 1). Additionally, 
HBD-1 mRNA was detected in a significantly higher 
number of placenta samples from HIV-1 positive 
mothers (20/36; 55.6%) compared to samples from 
HC mothers (7/38; 18.4%) (p=0.002; figure 1). In 
addition, HIV-1 positive mothers had a significantly 
higher HBD-1 expression in placental tissue than 
HIV-1 negative mothers (p= 0.004; figure 2a). 
HBD-3 mRNA was detected in 21 of 36 (58.3%) 
placenta samples from HIV-1 positive mothers, 
and in 24 of 38 (63.2%) placenta samples from 
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seronegative mothers; this difference was not 
statistically significant (p=0.81; figure 1). However, 
when HBD-3 mRNA levels were analyzed, a 
significantly lower expression was observed in SP 
than in HC mothers (p=0.017; figure 2b).
Correlation between HBD expression and SNP 
genotype
To verify if the presence of SNPs was associated 
with a differential antimicrobial peptide production, 
the presence of different genotypes in all groups 
was correlated with (1) the percentage of positive 
samples for HBD-1 or HBD-3, or both and (2) 
HBD mRNA expression level. Only one significant 
correlation was observed between the presence 
of both the A692G A/G and A1836G G/G SNPs 
Figure 1.  The percentage of placenta samples confirmed as 
positive for HBD-1, for HBD-3, and for both (HBD-1 and HBD-3) 
in HIV-positive and HIV-negative mothers.
Figure 2. HBD-1 and HBD-3 mRNA expression level in placenta from SP and HC mothers. 
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genotypes and a high percentage of positive 
samples for HBD-1 (p=0.0391).
No correlation between HBD expression and 
mother-child HLA-I discordance
Class I MHC was characterized to learn if the 
HLA discordance was associated with a higher 
antimicrobial peptide production. The degree of 
allele concordance was correlated with percentage 
of samples positive for HBD-1/HBD-3, and with HBD 
mRNA expression level. No significant correlations 
were observed, suggesting that HLA discordance 
was not related with HBD expression. However, 
due to the small sample size, additional studies will 
be necessary to reenforce this finding.
No correlation between HBD expression level 
and immunological state of the HIV-1 positive 
mothers
Finally, no significant correlations were observed 
between HBD-1 and HBD-3 mRNA levels with  viral 
load (r=0.199, r=0.141, respectively) and CD4+ T 
cell count (r=-0.299, r=0.288). This indicated that 
HBD mRNA levels were not influenced directly by 
the viral load or the immune status of the infected 
mother.
Discussion
The low rate of infection exhibited by ESN neonates 
born to HIV-1 SP mothers even in absence of 
preventive measures (16,17) has suggested the 
existence of natural mechanisms that prevent this 
infection during gestation. However, the mechanisms 
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that avoid HIV-1 vertical transmission have not 
been fully described and represent an important 
research target. The rate of vertical transmission 
decreases markedly, from 15%-35% to 0.8%-3%, 
when pregnant women are given zidovudine 
(AZT) early in pregnancy and when their children 
are delivered by cesarean section (7-9). In the 
current study, all HIV-1 positive mothers but one 
were treated to reduce the possibility of vertical 
transmission. Here, in these cases, therefore, the 
lack of infection may have been due to combination 
of factors, making it difficult to specify the individual 
role in natural resistance to HIV-1.
The fetus can acquire the HIV-1 as early as eight 
weeks of gestation (12), and infection possibly 
result from an alteration of the maternal-fetal barrier 
or an interaction of infected cells with trophoblastic 
cells or by HIV-1 transcytosis (15). Antiretrovirals 
are administered to HIV-1 positive mothers late in 
pregnancy; therefore, the HBDs or other antiviral 
soluble factors must play their protective role early 
in pregnancy. However, in the current study, HBD 
expression was not associated with protection 
against HIV-1 infection.
Although the gestational age at delivery and 
the type of delivery (vaginal vs cesarean) were 
significantly different between HIV-1 negative and 
positive mothers (p=0.0006; p<0.0001, respectively; 
table 1), previous reports have not associated these 
variables with a differential expression of defensins. 
However, these differences are not the issue since 
defensins are expressed early in pregnancy, being 
promoted by the cytokne environment and other 
infectious agents as previosly reported (53). The 
proposal here is that those HIV-1 stimuli and the 
SNPs in the DEFB1 gene can differentially modulate 
the expression levels of HBDs mRNA, and these 
proteins serve as a defense mechanism involved 
in protecting against HIV-1 vertical transmission in 
early pregnancy.
The most important mechanism identified for natural 
resistance is the ∆32 mutation in the CCR5 
gene (25). However, the homozygous genotype 
(∆32/∆32) was not encountered in the evaluated 
population; the ∆32/CCR5 heterozygotes were 
found in two newborns each of SP and HC 
mothers. These results agree with previous studies 
that have reported no association between the 
presence of the ∆32 allele and reduced risk of 
perinatally acquired HIV-1 infection (22,26,27). Other 
mechanisms proposed for the natural resistance to 
HIV-1 have included soluble factors with antiviral 
properties for preventing vertical transmission (28-
30,32,33,54,55).
Recent studies have shown that HIV-1 induces 
expression of HBD-2 and -3 in normal human oral 
epithelial cells and that these peptides inhibit HIV-1 
replication through direct binding to the virus and by 
CXCR4 down regulation (40,41). HBDs expressed 
by fetal membranes and the placenta (34,36) may 
create a key barrier to the establishment of different 
infections (34). However, HBD expression levels at 
placenta and other reproductive tissues have not 
been studied as potential modifiers of the risk of 
HIV infection. In addition, the role of HIV-1 in the 
induction of HBDs in these tissues has not been 
explored. The current study quantified the HBD-1, 
2 and 3 mRNA from placenta samples of HIV-1 
positive mothers and HC by real time RT-PCR. The 
percentage of placenta samples from SP mothers 
expressing HBD-1 mRNA was found in comparison 
higher that among  HC mothers (figure 1). Similarly, 
relative mRNA units of HBD-1 were significantly 
increased in placenta samples from SP mothers 
compared to samples from HC (figure 2a).
Previous reports have indicated that HBD-1 is 
constitutively expressed in placenta (39). The 
current results may indicate that in SP individuals, 
the virus has an inducing effect on the expression 
of HBD-1, but the effect is modulated by the genetic 
background and gene interactions. This issue re-
quires further assessment; however, in support of 
these observations, other studies have indicated an 
up-regulation of HBD-1 during the course of infection 
and the occurrence of inflammatory processes such 
as genital lichen sclerosus (56), inflamed dental 
pulps (57) and chronic sialadenitis (58).
The percentage of placentas positive for the 
HBD-3 defensin was similar in both groups (figure 
1). However, the relative levels of its transcript 
units were increased in placenta samples from 
HC mothers compared to those from SP mothers 
(figure 2b). Possibly, in vivo exposure to HIV-1, 
under certain circumstances, down-regulates the 
expression of some soluble factors, including 
HBD-3. In this regard, HBD-3 promoter is known 
to contain a functional binding site for the activator 
protein 1 (AP-1) (59); AP-1-convergent signaling 
pathways [for example those of toll-like receptor 
(TLR), and particularly TLR-2] are upstream 
events in the regulation of HBD-3 expression (59). 
Furthermore, all TLRs are expressed in human 
placenta (60,61) and it is known that HIV-1 inhibits 
the normal activation of these receptors leading to a 
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down-regulation of their downstream gene products 
(62,63). Therefore, the down-regulation of HBDs by 
HIV-1 probably occurs through the inhibition of 
normal activation of some receptors and different 
transcription factor signaling pathways such as AP-1.
Furthermore, the TH2 cytokines IL-4, IL-10, and 
IL-13 have shown to down-regulate the HBD-3 
expression on keratinocytes (64), but are 
upregulated during pregnancy (65) and are also 
induced by HIV-1 (66,67). Therefore, HIV-1 may 
induce an over-expression of this cytokine profile, 
thereby decreasing the levels of HBD-3 in placenta 
tissue of seropositive mothers. These observations 
support the hypothesis of the differential expression 
of HBDs induced by HIV-1 stimuli in placenta.
The search for SNPs in DEFB1, DEFB4 and 
DEFB103 genes; which code for HBD-1, 2 and 
3 respectively, represent a remarkable tool in 
their association with susceptibility to several 
infectious diseases and in particular with HIV-1. 
DEFB4 and DEFB103 genes exhibit normal copy 
number variation (68) and most likely their allelic 
distribution is in accordance with the Hardy-
Weinberg equilibrium (69,70). However, the DEFB1 
gene does not exhibit this phenomenon (69) and 
thereby becomes an excellent target for the search 
of SNPs associated with degree of susceptibility.
Although the anti-HIV-1 role of HBD-1 has not been 
previously reported, an association between SNPs 
in DEFB1 and the risk of acquiring HIV-1 infection 
has been suggested (44-47). In our group, studies 
have indicated that the A692G polymorphism 
is associated with resistance to HIV-1 infection 
among discordant couples (42). In asociation with 
the observation that placenta samples from SP 
mothers exhibited a significantly higher expression 
of HBD-1 mRNA compared to the placenta tissue 
from HC mothers (figure 1 and 2a), 3 SNPs were 
identified in the DEFB1 gene (A692G, G1654A, 
A1836G). These SNPs have been reported to be in 
high frequencies in several ethnic populations (43), 
and have characteristics that plausibly link them 
to differential gene expression or gene product 
function.
The current study examined the association of SNPs 
in DEFB1 gene with differential HBDs production, 
and compared the presence of several genotypes 
with the percentage of samples positive for HBD-1 
and HBD-3, as well as with HBD mRNA expression 
level. Only the simultaneous presence of A692G 
A/G and A1836G G/G genotypes was correlated 
significantly with the high percentage of positive 
samples for HBD-1 (p=0.04). However significant 
difference was observed between SP and HC 
mothers, although this may be a consequence of 
the small sample size. The A1836G SNP has been 
positioned within a probable polyadenylation site 
this mutation possibly affects the transcription or 
translation of the gene (43). These authors also 
suggest that SNP A692G can be recognized by the 
transcription factor NFkB (43) and thereby regulates 
the HBD-1 production. Because the A allele in the 
A692G SNP has been previously associated with a 
reduction in the HBD-1 expression compared to the 
G allele (71), it is likely that the presence of A1836G 
G/G and not the A692G A/G SNP explains the up-
regulation of the HBD-1 expression. The functional 
effect of the DEFB1 SNPs is still controversial 
(71,72) and requires more comprehensive studies. 
The G1654A SNP is adjacent to the first of six 
conserved cysteine residues and potentially has 
an effect on the folding of the peptide, thereby 
affecting peptide function (43). In the current 
study population, only the G allele in G1655A SNP 
occurred and therefore comparisons of its effects 
were not possible.
No differences in genotype and allele frequencies 
were detected between the experimental groups for 
any of the SNPs evaluated (table 2). The genotype 
frequencies were in Hardy-Weinberg equilibrium, 
except the SNP A692G in the newborn of SP-
mothers (table 3). The deviation in allele frequency 
may be due to the following causes: (1) the small 
sample size leading to a perception of genetic drift, 
or (2) negative selection for the normal genotype. 
The probability that this pattern was due to chance 
is very low (p<0.0001). However, the relationship 
of the A692G SNP to HIV-1 susceptibility was not 
evaluated since none of the newborns had acquired 
a perinatal HIV-1 infection.
In sum, these results suggested that the increased 
levels of HBD-1 found in placenta from HIV-1 positive 
mothers was due to viral stimuli and potentially 
represent one of the mechanisms for avoidance 
of vertical transmission of HIV-1. In contrast, the 
virus appears to down-regulate HBD-3. Finally, 
the analysis of three SNPs in the DEFB1 gene did 
not elucidate the role of these genetic variants in 
the HBD-1 function, although the A692G A/G and 
A1836G G/G genotypes may provide a partial 
explanation for the increased expression of HBD-1 
in placental tissue. 
In conclusion, the HIV-1 stimuli and the SNPs in 
the DEFB1 gene are proposed to differentially 
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modulate the expression levels of HBDs, and 
these proteins are a potential defense mechanism 
protecting against HIV-1 vertical transmission in 
early pregnancy.
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